We just covered the 10 Best Stocks to Buy Right Now According to AI and Eli Lilly and Company (NYSE:LLY) ranks 4th on this list.
Eli Lilly and Company (NYSE:LLY) is a premier global pharmaceutical corporation dedicated to discovering, developing, and manufacturing innovative human medicines across multiple therapeutic areas
The company’s primary growth catalyst is its world-class cardiometabolic health portfolio, led by the highly successful tirzepatide molecule, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Eli Lilly also maintains a prominent market presence in oncology with Jaypirca, immunology with Omvoh and Ebglyss, and neuroscience with Kisunla, an advanced treatment targeting Alzheimer’s disease. Eli Lilly and Company (NYSE:LLY) relies on heavy reinvestment into clinical research and development, combined with expansion of global manufacturing capacity.
The firm recently posted the Q1 2026 financial report that recorded total revenue of $19.8 billion, representing a 56% year-over-year increase, fueled almost entirely by the demand for Mounjaro and Zepbound, which collectively brought in $12.8 billion. Non-GAAP diluted earnings per share skyrocketed by 156% year-over-year to $8.55, vastly exceeding analyst forecasts of $6.97. Eli Lilly maintained a superb gross margin of 82.6%, while its non-GAAP performance margin expanded by 7 percentage points to 50%.